ABANDONED - NO STATEMENT OF USE FILED
no statement of use filed
on 05 Jun 2023
Last Applicant/ Owned by
One Johnson & Johnson Plaza
New Brunswick
NJ
08933
Serial Number
88899441 filed on 04th May 2020
Registration Number
N/A
Correspondent Address
Cheryl L. Foytlin
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
RETELPRI
Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory dis Read More
Classification Information
Class [005]
Pharmaceutical Products
Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, digital ulcers, and cerebrovascular diseases; vaccines; anxiolytics; anti-allergics; anti-infectives
Mark Details
Serial Number
No 88899441
Mark Type
No Service/Collective Mark
Attorney Docket Number
No T41121US2
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 05th Jun 2023 | ABANDONMENT - NO USE STATEMENT FILED |
| 05th Jun 2023 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| 29th Oct 2022 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 27th Oct 2022 | SOU EXTENSION 4 FILED |
| 27th Oct 2022 | SOU EXTENSION 4 GRANTED |
| 27th Oct 2022 | TEAS EXTENSION RECEIVED |
| 20th Apr 2022 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 18th Apr 2022 | TEAS EXTENSION RECEIVED |
| 18th Apr 2022 | SOU EXTENSION 3 GRANTED |
| 18th Apr 2022 | SOU EXTENSION 3 FILED |